Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | TC-110 T-cells |
Synonyms | |
Therapy Description |
TC-110 T-cells consist of T-lymphocytes engineered to express a CD19-targeting T cell receptor linked to a binder domain, which potentially induces a T-cell response against tumor cells with reduced inflammation (Cancer Res 2019;79(13 Suppl):Abstract nr 2330). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
TC-110 T-cells | CD19 Immune Cell Therapy 62 | TC-110 T-cells consist of T-lymphocytes engineered to express a CD19-targeting T cell receptor linked to a binder domain, which potentially induces a T-cell response against tumor cells with reduced inflammation (Cancer Res 2019;79(13 Suppl):Abstract nr 2330). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04323657 | Phase Ib/II | Cyclophosphamide + Fludarabine TC-110 T-cells | TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia | Completed | USA | 0 |